CytRx to Present at the 2013 Leerink Swann Global Healthcare Conference

  CytRx to Present at the 2013 Leerink Swann Global Healthcare Conference

Business Wire

LOS ANGELES -- February 6, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, announced that President and CEO Steven A.
Kriegsman and Vice President of Business Development David J. Haen will
present at the 2013 Leerink Swann Global Healthcare Conference on Thursday,
February 14, 2013, at 1:30 p.m. Eastern time (10:30 a.m. Pacific time). The
conference is being held at the Waldorf=Astoria Hotel in New York City.

A webcast of the presentation will be available on the Company’s website at
http://cytrx.com/investors/presentations.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. The CytRx oncology pipeline includes two programs in
clinical development for cancer indications: aldoxorubicin (formerly known as
INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate
aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as
a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical
trial primarily in the same indication, and has initiated a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors and a
Phase 1b study of aldoxorubicin in combination with doxorubicin in patients
with advanced solid tumors. The Company has held a positive meeting with the
FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy, and has submitted a special protocol
assessment related to this trial. Tamibarotene is being tested in a
double-blind, placebo-controlled, international Phase 2b clinical trial in
patients with non-small-cell lung cancer. The Company completed its evaluation
of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in
high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a
partner for further development of bafetinib. For more information about CytRx
Corporation, visit www.cytrx.com.

Contact:

Investor Relations
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com
 
Press spacebar to pause and continue. Press esc to stop.